Sign in
Active, not recruitingPhase 3

Study of OT-101 in Treating Myopia

Key facts

Who runs it
Ocumension (Hong Kong) Limited
Where
Cleveland, Colorado Springs, Cranberry Township, Erie, Fort Collins, Gainesville, Indianapolis, Jacksonville, Memphis, Mint Hill, Pittsburgh, Rockville, San Antonio, Shelby, and Washington, United StatesSee the 15 sitesAlso in 5 other countries, 16 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
678 people, planned
Started
1 Apr 2021
Expected to end
Apr 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • OT-101 Ophthalmic Solution
  • Vehicle
Record updated
8 August 2023

Who can take part

Age
3 years to 15 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Have refractive error by cycloplegic autorefraction at baseline (Visit 1) in the study eye of:; myopia greater or equal to -1.00D of spherical equivalent; astigmatism less than or equal to 1.50DC; progression of at least -0.50D of spherical equivalent in the last 12 months

Who cannot take part

  • Have undergone any myopia control treatment including orthokeratology, rigid gas-permeable contact lenses, bifocal contact lenses, progressive addition spectacle lenses, or other lenses to reduce myopia progression in the previous 6 months. Myopic correction in the form of single-vision eyeglasses and/or single-vision soft contact lenses are allowed
  • Have undergone any form of refractive eye surgery including incisional keratotomy, photorefractive keratectomy [PRK], laser in situ keratomileusis [LASIK], laser-assisted sub- epithelial keratectomy [LASEK]), corneal inlay procedures, conductive keratoplasty, small incision lenticule extraction (SMILE), cataract extraction, or any form of intraocular lens implantation
  • Have active or a history of chronic or recurrent episodes of ocular inflammation (e.g. moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis) in either eye

Where in United States

Also in 5 other countries, 16 sites

  • University Hospitals Cleveland Medical Center*Cleveland, United States
  • Colorado Vision InstituteColorado Springs, United States
  • Scott & Christie and AssociatesCranberry Township, United States
  • Pediatric Ophthalmology of Erie, IncErie, United States
  • Eye Center of Northern Colorado, PCFort Collins, United States
  • Family FocusGainesville, United States
  • Indiana University Health Physicians Pediatric OphthalmologyIndianapolis, United States
  • Pediatric Eye Consultants of North FloridaJacksonville, United States
  • Total Eye Care, P.A.Memphis, United States
  • Pure Ophthalmic ResearchMint Hill, United States
  • UPMC Children's HospitalPittsburgh, United States
  • Kids Eye Care of MarylandRockville, United States
  • San Antonio Eye CenterSan Antonio, United States
  • CORE, Inc.Shelby, United States
  • Comprehensive Eye Care, Ltd.Washington, United States

About the trial

What the trial wants to find out

This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects

The 3 groups in the trial

  • OT-101 aloneTreatment being tested

    Atropine Sulfate 0.01% Ophthalmic Solution through year 4

    Treatment: OT-101 Ophthalmic Solution

  • OT-101 plus vehicleTreatment being tested

    Atropine Sulfate 0.01% Ophthalmic Solution through year 3 followed by vehicle for 1 year

    Treatment: OT-101 Ophthalmic Solution and Vehicle

  • VehiclePlacebo, for comparison

    Vehicle (Investigational Product minus active ingredient) through year 4

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects
Record updated
8 August 2023